Articles tagged with Tumor Cells
A team from Technical University of Munich has discovered a 'shut-off switch' in immune cells called PD-1 that prevents T cell Non-Hodgkin's lymphoma. The study found that PD-1 can turn off defective T cells at an early stage, preventing them from becoming tumor cells.
A new treatment aims to direct an immune response against a misshapen protein found exclusively on cancer cells, offering hope for children with deadly diffuse intrinsic pontine glioma. The protein target is a neoantigen that can be used to develop more selective and potent immunotherapies.
Researchers found that leftover cancer cell debris can stimulate tumor growth, but resolvins can block this response. The study suggests a new approach to enhance cancer therapy and prevent recurrence.
A new method using single-cell genomics can help identify potentially lethal prostate tumors before surgery, improving risk assessment and treatment decisions. The approach analyzes genomic patterns in biopsy cores, assigning a score based on clonality and genetic aberrations.
Researchers discovered that chemotherapy can stimulate tumor growth by inducing an inflammatory reaction in the body. Resolvins, a family of molecules, have been found to suppress this response, suggesting new ways to enhance cancer therapy effectiveness.
Research reveals that bone marrow-derived cells contribute to lung cancer progression by stimulating the production of specific neutrophils. These neutrophils exhibit increased expression of genes associated with tumor-promoting processes, leading to worse patient survival in a small study.
Researchers at Beth Israel Deaconess Medical Center have shown that chemotherapy-generated debris can stimulate tumor growth, but resolvins can suppress this effect. The findings offer a novel treatment approach to prevent cancer recurrence.
A new study at the University of Michigan identifies a pathway that links efferocytosis, the process of removing dead cells, to tumor growth in metastatic prostate cancer. The researchers found that a pro-inflammatory protein called CXCL5 accelerates tumor growth and sheds light on novel effective cancer therapies.
Researchers have identified a possible way to reengage a tumor suppressor protein, Growth Differentiation Factor 11, in triple-negative breast cancer cells. This could lead to the development of novel medications that can stop the aggressive form of cancer by intervening in its progression.
Scientists at NIST have discovered a way to make tiny colonies of cells grow in three-dimensional structures inside petri dishes, paving the way for more realistic biological environments for testing pharmaceuticals. The method could help bridge the gap between lab and living creature testing, speeding up drug development.
Researchers have developed a novel approach to combat cancer using synthetic designer cells that mimic T-cells. These cells can detect and kill cancer cells while minimizing side effects, offering a promising new treatment option.
Researchers discovered a novel form of crosstalk among tumor cells and immune cells that inhibits the effectiveness of immunotherapeutic strategies. Combining CSF-1R inhibitors with selective CXCR2 inhibitors shows significant anti-tumor effects, suggesting new approaches to enhance therapeutic efficacy.
Researchers at Queen Mary University of London used CRISPR-dCas9 epigenetic editing to cause healthy breast cells to undergo 'hyperproliferation', a key early stage of tumour initiation. The findings could lead to the development of new biomarkers for earlier diagnosis and novel therapies.
Researchers discovered that cells retain properties from their previous environment for several days, known as mechanical memory. This property can aid in tumor invasion and metastasis. The study's findings may lead to new insights into the mechanisms behind cancer spread.
Researchers discovered that different types of brain tumors and brain cancer cells share common energy production processes, enabling them to adapt and grow in the brain. This study aims to identify new targets for treatment and potentially develop drugs specifically designed to target these survival mechanisms.
Researchers argue that identifying molecular subtypes of different cells within tumors can improve breast cancer treatment. They advocate for more accurate diagnostic tests to capture irregularities between tumor cells, which are often treated as a whole.
For-Robin's monoclonal antibody JAA-F11 successfully targets and kills human breast cancer cells in human tumors grafted into mice, effectively treating triple-negative breast cancer. The company is now focusing on fundraising and preparing for human clinical trials to bring its product from the bench to the bedside.
Researchers at the Francis Crick Institute have identified a novel protein that exclusively targets Wnt signalling in tumour cells, reducing growth of colon cancer cells without harming healthy cells.
Researchers have identified melanocytes as the origin of cutaneous melanoma, a deadly form of skin cancer. These cells are reprogrammed to become invasive and migratory cancer cells, leading to tumor formation.
Researchers at the Wyss Institute for Biologically Inspired Engineering have developed a human lung-on-a-chip technology that models the growth and metastatic behaviors of non-small cell lung cancer. The study found that tumor cells grow rampantly in the alveolar microenvironment but remain quiescent in the airway chip, and that cyclic...
International experts have identified a new protein called ZATT that can directly clean DNA breaks without degradation, allowing for more efficient repair and potentially increasing chemotherapy sensitivity. This breakthrough has the potential to improve treatment outcomes and enable personalized therapies.
A new computer program called SCENIC enables researchers to quickly and accurately identify different cell types in the human body. The method helps understand how cell fate is regulated and could lead to the discovery of master regulators and potential drug targets.
Researchers have developed a new software tool that reveals molecular connections between breast cancer tumor cells and immune system cells in the bloodstream. The study found that these connections vary depending on the type of breast cancer, potentially leading to new treatment and monitoring strategies.
The UA Cancer Center's research may lead to ways to target metastatic tumors by altering the depth of quiescence in cancer cells. This could make it easier for chemotherapy drugs to target and kill these cells.
Researchers at Cologne University Hospital have discovered a novel inhibitor that specifically targets NMC tumours, a rare and lethal form of cancer. The study's findings provide valuable insights into the molecular mechanism responsible for the effectiveness of the inhibitor, paving the way for new and improved therapies.
Researchers at Children's Hospital Los Angeles identified a molecular pathway in an immune cell called a tumor-associated macrophage that supports neuroblastoma, a pediatric cancer. Targeting the STAT3 pathway with a clinically available drug may be a promising approach to improve outcomes for children with high-risk neuroblastoma.
Researchers at Weizmann Institute of Science find that oxygen-starved killer T cells are more effective at destroying cancerous tumors and outperform regular T cells in a mouse model. The study suggests an easy improvement to existing immunotherapy protocols.
Scientists discovered how cancer-fighting Natural Killer cells power up and how cholesterol-like molecules cut them off. Activated NK cells use a unique energy production system that can be disrupted by oxysterols, which may explain poor performance in patients with high cholesterol levels.
Researchers at The Wistar Institute have discovered a novel metastasis suppressor pathway orchestrated by the mitochondrial protein SNPH. This pathway promotes tumor cell proliferation in local growth but inhibits invasion and metastasis. By studying SNPH, scientists may uncover new therapeutic approaches to target metastatic cells.
A new blood test can predict how early-stage lung cancer patients will fare, identifying clusters of aggressive tumor cells that indicate shorter survival times. The test uses circulating tumor cells in the bloodstream to monitor cancer progression and resistance to treatments.
Researchers suggest that combining drugs blocking PAF-R protein may increase radiotherapy's killing of tumor cells by one third and reduce tumor repopulation. Analysis with human oral cancer cells and murine cervical cancer cells showed promising results, supporting a new therapeutic strategy.
Researchers at UT Southwestern Medical Center report that tumors stressed by cancer immunotherapy release mitochondrial DNA into nearby immune cells, triggering a host alert system. This discovery highlights the critical role of cGAS as an innate immune sensor for DNA and its importance in bridging the body's two immune systems.
A compound has been identified that enhances tumor-targeting viruses' ability to selectively kill liver cancer cells while sparing healthy ones. The oncolytic virus M1 was boosted by combining it with Eeyarestatin I, increasing its potency 3,600-fold against cancer cells in culture and animal models.
A new blood test developed by TUM researchers can predict drug resistance in patients with advanced prostate cancer, analyzing AR-V7 RNA molecules for early detection. The test has shown high sensitivity and accuracy, identifying approximately one-fifth of patients with large amounts of resistant tumor cells.
Researchers at Lund University identified a specific marker (CD44) that interacts with protein HIF-2a, allowing cancer stem cells in glioblastoma to adapt to oxygen deprivation. This interaction enables the growth of more aggressive tumor cells, which are resistant to treatment and contribute to recurrence.
Researchers have designed a complex sugar molecule that binds to galectin-1, enabling the immune system to recognize and attack tumor cells. This breakthrough could lead to the development of new drugs and rapid tests for early cancer detection.
A research team at Lund University has discovered that gene expression in normal tissue varies depending on the location within the kidney. This variation affects the accuracy of comparisons between tumour cells and healthy tissue, leading to a better understanding of kidney cancer subtypes.
Researchers at the University of Portsmouth have identified two molecules, CD15s and CD62E, that play a key role in brain tumor cells binding to blood vessels. By blocking these molecules, it may be possible to prevent brain tumors from developing in patients with non-small cell lung cancer.
Researchers at Dartmouth's Norris Cotton Cancer Center have discovered a novel synthetic lethality screen to discover molecules that target genetically modified yeast lacking NF1. The team identified one lead candidate called Y100, which disrupts tumor cell growth and induces oxidative stress causing death of NF1-deficient cancer cells.
A new study led by Princeton University researchers finds that cells must move around and change shape to gain a meaningful understanding of their environment. The typical cell's environment is highly varied in stiffness or flexibility, making it difficult for the cell to determine its surroundings through mechanosensing.
New research reveals a mechanism driving cell cannibalism in tumors, suggesting it may resist cancer growth. Weakened cell attachments trigger entosis, where one cell kills and digests another, potentially slowing or preventing tumor growth.
Researchers design multifunctional nano-theranostics targeting the unique acidic tumor microenvironment. These smart imaging nanoprobes enable sensitive and accurate tumor diagnosis through signal amplification under reduced pH conditions.
Researchers developed an engineered opsonin protein to capture CTCs in the bloodstream, reducing detection time and increasing efficiency. The technology shows promise for improving cancer diagnostics by targeting specific carbohydrate molecules on CTCs.
Scientists have developed a bioorthogonal labeling approach to identify sialylated glycoproteins in prostate cancer tissue, which could serve as tumor markers. The method allows for direct assessment of tumor metabolism in its natural environment, providing insights into cancer biology.
Researchers at OIST have discovered a new photosensitizer that targets brain cancer cells with improved efficiency, using the naturally occurring amino acid taurine to enhance its effectiveness. The study shows promise for developing more effective brain cancer treatments through photodynamic therapy.
Researchers at Université de Genève discovered that healthy fibroblasts surrounding breast cancer cells have a unique variant of the estrogen receptor GPER in their nuclei. This genetic variation promotes tumor cell migration and invasiveness through the secretion of molecules that stimulate malignant growth.
Researchers found that combining peptide-receptor radionuclide therapy (PRRT) with a PARP inhibitor significantly slows the growth of neuroendocrine tumors. The treatment combination induced more cell death and inhibited cell proliferation in both gastroenteropancreatic and bronchopulmonary NET cell lines.
Scientists from Griffith University and partners have engineered a new tool to detect cancer by recognizing an unusual sugar present on tumor cells. The innovation utilizes the E. coli toxin, which binds to Neu5Gc, a substance produced by tumor cells.
Scientists at Johns Hopkins created a nanoparticle that carries two different antibodies to simultaneously switch off cancer cells' defensive properties while switching on a robust anticancer immune response in mice. The 'immunoswitch' particles dramatically slowed the growth of mouse melanoma and colon cancer, even eradicating tumors.
Researchers at University of California San Diego School of Medicine found that cancer cells exploit the unfolded protein response (UPR) to activate Wnt signaling, promoting tumor survival and drug resistance. This mechanism enables cancer cells to cope with nutrient deprivation and therapies, contributing to intra-tumor heterogeneity.
F8-TNF stimulates killer cells to target sarcomas by identifying them through dormant viral proteins, offering a new avenue for cancer immunotherapy. The treatment has been shown to completely cure mice of sarcoma and grant immune protection against tumor recurrence.
Researchers at German Cancer Research Center (DKFZ) found a substance that blocks cancer-promoting metabolic products in leukemia and brain tumors. The investigational compound BAY1436032 is effective against AML and glioblastomas, reducing stem-cell properties and tumor cell growth.
Researchers have developed a chemical array technique that can identify and culture malignant stem-like cells within melanoma tumors. This allows for the creation of patient-specific models for individualized cancer treatment.
Moffitt researchers demonstrate that mathematical models can be used to predict how different tumor cell populations interact with each other and respond to environmental changes. By applying small biological forces, they show that complex systems like cancer can be steered into a less invasive growth pattern.
AbeXXa Biologics identifies targets for cancer treatment from thousands of intracellular proteins, potentially resulting in effective immunotherapies for broad patient groups. The company is developing T cell receptor-like antibody-drug complexes to kill tumor cells with low peptide/HLA targets.
Researchers used C. elegans to identify a genetic signature of mesodermal-epithelial communication involved in human cancer cell proliferation. The study uncovered 33 genes conserved between worms and humans that control this network, providing a roadmap for new cancer therapies.
A study published on Nature Communications reveals that breast cancer cells undergo a stiffening state prior to acquiring malignant features and becoming invasive. This discovery identifies a new signal in tumor cells that can be further explored when designing cancer-targeting therapies.
Researchers discovered that residual tumor cells display alterations in fat metabolism and oxidative stress, which contribute to DNA damage and cancer relapse. Targeting metabolic pathways in these cells could potentially prevent recurrence.
Researchers at EMBL found that residual breast cancer cells have specific traits that distinguish them from healthy cells and seem to cause relapse. The study suggests lipid metabolism as an exciting therapeutic target to reduce breast cancer recurrence.
Research reveals how hypoxia leads to inhibition of miR-34a, a key tumor suppressor, promoting metastasis and EMT. The findings suggest that targeting this process with drugs could be a therapeutic approach for treating metastasizing colon tumors.